Amsden G W, Nafziger A N, Foulds G
Clinical Pharmacology Research Center, Departments of Pharmacy and Medicine, and Research Institute, Bassett Healthcare, Cooperstown, New York 13326, USA.
Antimicrob Agents Chemother. 1999 Jan;43(1):163-5. doi: 10.1128/AAC.43.1.163.
The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days.
在12名健康志愿者中，比较了口服1500毫克阿奇霉素的3天（第1至3天，每天500毫克）和5天（第1天500毫克，第2至5天每天250毫克）给药方案在血清和白细胞（WBC）中的药代动力学。从每个给药方案开始后的12天内收集血清、多形核白细胞和单核白细胞。研究结果表明，两种给药方案的血清和两种类型白细胞的暴露情况相似。第12天白细胞中的药物浓度远高于所有相关社区获得性呼吸道病原体的最低抑菌浓度（MIC）。两种给药方案在血清中的终末半衰期基本相等，均为66小时，与既往报道一致。这些结果表明，标准的1500毫克口服阿奇霉素剂量可以在5天或3天内给药。
